References
- Hofmann W K, Ottman O G, Ganser A, et al. Myelodysplastic Syndromes: Clinical Features. Sem Hematol 1996; 33: 177–85
- Negrin R S, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 1996; 87: 4076–84
- List A F. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Sem Oncol 1999; 26: 61–5
- List A F, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364–9
- Bowen D, Denzlinger C, Brugger W, et al. Poor response rate to a continuous schedule of Amifostine therapy for “low/intermediate risk” patients. Br J of Haematol 1998; 103: 785–7
- Ganser A, Hoelzer D. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Sem Hematol 1996; 33: 186–95
- Greenberg P L. Treatment of myelodysplstic syndromes with hemopoietic growth factors. Sem Oncol 1992; 19: 106–17